OctoPlus expands development agreement with ESBATech on controlled release product for ophthalmic indications

24-Feb-2011 - Netherlands

OctoPlus N.V. announced that it has signed a contract with ESBATech, an Alcon Biomedical Research Unit, to develop a controlled release formulation for one of its proprietary biological compounds for ophthalmic applications.

The project includes process development, scale-up and manufacturing for pre-clinical studies. Financial details are not disclosed, but the project will make a material contribution to our annual revenues in 2011. In addition to Locteron®, this programme will be part of our portfolio of projects utilising our proprietary technologies.

This drug delivery technology evaluation project started in 2009. OctoPlus evaluated the feasibility of a controlled release formulation that combines a proprietary eye care ingredient of ESBATech with our drug delivery technology PolyActive®.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances